Top Clinical Takeaways The FDA's RMAT designation for KYV-101 highlights the potential of this CAR T-cell therapy to transform treatment for myasthenia gravis. KYV-101 specifically targets the CD19 protein on B cells, a key factor in various autoimmune diseases. Kyverna Therapeutics is exp...